It is projected that the prevalence of tobacco smoking will be 15.4 percent by 2025, a decrease from a prevalence of 27 percent in the year 2000. This statistic depicts the prevalence of tobacco smoking worldwide from 2000 to 2020 and projections for 2025.

According to the data, it is projected that the prevalence of tobacco smoking among those living in Africa will decrease from around 14.5 percent in 2000 to 7.4 percent in 2025. This statistic depicts the prevalence of tobacco smoking worldwide from 2000 to 2020 and projections for 2025, by region.

ObjectiveIn Sweden, previous favourable trends in blood cholesterol levels have recently levelled off or even increased in some age groups since 2003, potentially reflecting changing fashions and attitudes towards dietary saturated fatty acids (SFA). We aimed to examine the potential effect of different SFA intake on future coronary heart disease (CHD) mortality in 2025.MethodsWe compared the effect on future CHD mortality of two different scenarios for fat intake a) daily SFA intake decreasing to 10 energy percent (E%), and b) daily SFA intake rising to 20 E%. We assumed that there would be moderate improvements in smoking (5%), salt intake (1g/day) and physical inactivity (5% decrease) to continue recent, positive trends.ResultsIn the baseline scenario which assumed that recent mortality declines continue, approximately 5,975 CHD deaths might occur in year 2025. Anticipated improvements in smoking, dietary salt intake and physical activity, would result in some 380 (-6.4%) fewer deaths (235 in men and 145 in women). In combination with a mean SFA daily intake of 10 E%, a total of 810 (-14%) fewer deaths would occur in 2025 (535 in men and 275 in women). If the overall consumption of SFA rose to 20 E%, the expected mortality decline would be wiped out and approximately 20 (0.3%) additional deaths might occur.ConclusionCHD mortality may increase as a result of unfavourable trends in diets rich in saturated fats resulting in increases in blood cholesterol levels. These could cancel out the favourable trends in salt intake, smoking and physical activity.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

NRT Smoking Cessation Aids Market Outlook

The global market size for NRT (Nicotine Replacement Therapy) smoking cessation aids was valued at approximately $2.5 billion in 2023 and is expected to reach around $4.1 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.5% over the forecast period. The growth of the NRT smoking cessation aids market is driven by increasing awareness about the health risks associated with smoking, a rise in government initiatives to curb smoking rates, and advancements in cessation aid technologies.

One of the primary growth factors in the NRT smoking cessation aids market is the rising awareness of the health risks associated with smoking. Smoking is a leading cause of preventable diseases and deaths worldwide, including heart disease, stroke, and various forms of cancer. As public health campaigns and educational programs emphasize the dangers of smoking, more individuals are motivated to quit, thereby increasing the demand for cessation aids. Additionally, there is a growing recognition of the benefits of quitting smoking, such as improved cardiovascular health, reduced risk of cancer, and enhanced respiratory function, which further drives the market.

Government initiatives and regulatory support play a crucial role in the growth of the NRT smoking cessation aids market. Many governments around the world have implemented strict regulations on tobacco products, including higher taxes, advertising bans, and smoking bans in public places. These measures create a more challenging environment for smokers and encourage them to seek assistance in quitting. Moreover, several countries offer subsidized or free smoking cessation aids through their healthcare systems, making these products more accessible to a broader population. Such initiatives are instrumental in promoting smoking cessation and boosting the market for NRT aids.

Technological advancements and product innovations also contribute significantly to the market's growth. Over the years, manufacturers have developed a wide range of NRT products, including nicotine patches, gum, lozenges, inhalers, and nasal sprays, each catering to different preferences and needs of individuals trying to quit smoking. Continuous research and development efforts have led to the introduction of more effective and user-friendly products, enhancing the overall success rate of smoking cessation programs. Additionally, the advent of digital health platforms and mobile applications that provide personalized support and monitoring has further revolutionized the smoking cessation landscape.

The market for Smoking Cessation Products is expanding as more individuals seek effective solutions to quit smoking. These products, which include a variety of NRT options, are designed to help reduce withdrawal symptoms and cravings, making the quitting process more manageable. As awareness of the health risks associated with smoking continues to grow, so does the demand for these products. The availability of Smoking Cessation Products in various forms, such as patches, gum, and lozenges, ensures that there is a suitable option for every smoker, enhancing the chances of successfully quitting. Additionally, innovations in product formulations and delivery methods are making these products more effective and user-friendly, further driving market growth.

Regionally, North America dominates the NRT smoking cessation aids market, accounting for the largest market share. The high prevalence of smoking-related diseases, strong healthcare infrastructure, and increased awareness about the benefits of quitting smoking are key factors driving the market in this region. Europe follows closely, with significant contributions from countries like the UK, Germany, and France. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, attributed to the large smoking population, rising disposable incomes, and growing health consciousness among individuals. Latin America and the Middle East & Africa regions also show promising growth potential, driven by increasing government initiatives and rising healthcare expenditure.

Product Type Analysis

The NRT smoking cessation aids market is segmented by product type, including nicotine patches, nicotine gum, nicotine lozenges, nicotine inhalers, nicotine nasal sprays, and others. Each product type offers a unique approach to delivering nicotine and aiding in smoking cessation.

This table presents a wide variety of historical data in the field of health, lifestyle and health care. Figures on births and mortality, causes of death and the occurrence of certain infectious diseases are available from 1900, other series from later dates. In addition to self-perceived health, the table contains figures on infectious diseases, hospitalisations per diagnosis, life expectancy, lifestyle factors such as smoking, alcohol consumption and obesity, and causes of death. The table also gives information on several aspects of health care, such as the number of practising professionals, the number of available hospital beds, nursing day averages and the expenditures on care. Many subjects are also covered in more detail by data in other tables, although sometimes with a shorter history. Data on notifiable infectious diseases and HIV/AIDS are not included in other tables.

Data available from: 1900

Status of the figures:

2025: The available figures are definite.

2024: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, hiv, aids; - causes of death.

2023: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - number of hospital discharges and length of stay; - number of hospital beds; - health professions; - perinatal and infant mortality. Figures are revised provisional for: - expenditures on health and welfare.

2022: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - number of hospital discharges and length of stay; - number of hospital beds; - health professions. Figures are revised provisional for: - expenditures on health and welfare.

2021: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; Figures are revised provisional for: - expenditures on health and welfare.

2020 and earlier: Most available figures are definite. Due to 'dynamic' registrations, figures for notifiable infectious diseases, HIV/AIDS remain provisional.

Changes as of 4 July 2025: The most recent available figures have been added for: - population on January 1; - live born children, deaths; - persons in (very) good health; - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - use of medication; - sickness absence; - lifestyle; - use of health care services; - number of hospital discharges and length of stay; - number of hospital beds; - health professions; - expenditures on health and welfare; - healthy life expectancy; - causes of death.

Changes as of 18 december 2024: - Due to a revision of the statistics Health and welfare expenditure 2021, figures for expenditure on health and welfare have been replaced from 2021 onwards. - Revised figures on the volume index of healthcare costs are not yet available, these figures have been deleted from 2021 onwards.

When will new figures be published? December 2025.

Lung Cancer Treatment Drugs Market Outlook

The global lung cancer treatment drugs market size, which was valued at approximately USD 24 billion in 2023, is projected to reach around USD 50 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.3%. This remarkable growth can be attributed to the rising incidence of lung cancer worldwide, advancements in medical technology, and the increasing availability of targeted therapies and immunotherapies that have significantly improved patient outcomes.

One of the major growth factors driving the lung cancer treatment drugs market is the rising prevalence of lung cancer globally. As the leading cause of cancer-related mortality, lung cancer accounts for nearly 1.8 million deaths each year. Factors such as smoking, air pollution, occupational hazards, and genetic predispositions contribute significantly to the high incidence rates. The continuous efforts in public health campaigns to reduce smoking rates and promote early detection through screening programs have created a larger, more treatable patient population, thereby boosting the demand for effective treatment options.

Another key growth factor is the significant advancements in medical research and technology. Over the past decade, there has been a notable shift from traditional chemotherapy to more advanced targeted therapies and immunotherapies. These treatments are designed to attack specific cancer cells with minimal damage to surrounding healthy tissues, thereby enhancing the efficacy and reducing the side effects traditionally associated with lung cancer treatments. Breakthroughs in understanding the genetic and molecular profiles of lung tumors have paved the way for personalized medicine, which tailors treatment plans to individual patients, leading to better outcomes and prolonged survival rates.

Furthermore, the market is also driven by substantial investments in research and development (R&D) by pharmaceutical companies. These investments have led to the development of novel drugs and combination therapies that show promising results in clinical trials. Regulatory bodies, such as the FDA and EMA, have also expedited the approval processes for breakthrough therapies under their accelerated approval programs. Moreover, collaborations and partnerships between biotech firms and clinical research institutions have facilitated the discovery and commercialization of innovative lung cancer treatments.

Small Molecule Tumor Drugs have emerged as a pivotal component in the fight against lung cancer, particularly due to their ability to target and inhibit specific proteins involved in tumor growth and progression. These drugs are designed to interfere with the signaling pathways that cancer cells use to proliferate, thereby halting their advancement and potentially shrinking tumors. The development of small molecule inhibitors has been a game-changer, offering new hope for patients who may not respond well to traditional therapies. As research continues to unravel the complexities of cancer biology, small molecule drugs are expected to play an increasingly important role in personalized medicine, providing tailored treatment options that improve patient outcomes and quality of life.

The regional outlook for the lung cancer treatment drugs market indicates significant growth across various geographies. North America currently dominates the market due to the high prevalence of lung cancer, the presence of leading pharmaceutical companies, and robust healthcare infrastructure. Europe follows closely, driven by favorable government policies and high healthcare expenditure. The Asia Pacific region is expected to witness the fastest growth during the forecast period, owing to the increasing awareness about lung cancer, improving healthcare infrastructure, and rising disposable incomes in countries like China and India. Latin America and the Middle East & Africa are also expected to contribute to the market growth, albeit at a slower pace, due to improving diagnostics and treatment facilities.

Drug Class Analysis

The lung cancer treatment drugs market can be segmented by drug class into chemotherapy, targeted therapy, immunotherapy, and others. Chemotherapy, once the cornerstone of lung cancer treatment, involves the use of drugs that kill rapidly dividing cancer cells. Despite its effectiveness, chemotherapy is often associated with significant side effects, such as hair loss, nausea, and immunosuppression. However, it r

Lung Cancer Diagnosis and Therapeutics Market Outlook

The global market size for lung cancer diagnosis and therapeutics is poised for significant growth, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032. In 2023, the market was valued at approximately $28 billion, and it is anticipated to reach an estimated $55 billion by 2032. This robust growth can be attributed to the increasing prevalence of lung cancer worldwide, advancements in diagnostic technology, and the continuous development of innovative therapeutic options. As awareness of the disease rises and public health initiatives aim to improve early detection rates, the lung cancer diagnosis and therapeutics market is set to expand rapidly.

One of the primary growth factors for this market is the alarming increase in the incidence of lung cancer. Lung cancer remains one of the most common cancers globally, accounting for a significant number of new cancer cases and deaths each year. Factors such as smoking, exposure to environmental pollutants, and genetic predispositions contribute to the rising cases. Governments and healthcare organizations worldwide are focusing on early detection and prevention programs, thus driving demand for advanced diagnostic techniques and therapeutics. The adoption of low-dose computed tomography (LDCT) for screening high-risk populations is becoming more prevalent, aiding in early diagnosis and improved patient outcomes.

Technological advancements in diagnostic tests and therapeutic approaches are also a major driving force in this market. Innovations such as liquid biopsies, next-generation sequencing (NGS), and personalized medicine are revolutionizing the diagnosis and treatment processes. Liquid biopsies, for instance, offer a non-invasive method of detecting genetic mutations associated with lung cancer, leading to more precise and tailored treatment plans. Similarly, breakthroughs in targeted therapies and immunotherapies have opened new avenues for treating lung cancer, particularly for cases where traditional chemotherapy is less effective. The continuous development of novel drugs and combination therapies is expected to further propel market growth.

The increasing focus on research and development is another crucial factor fueling market expansion. Pharmaceutical companies and research institutions are investing heavily in the development of new drugs and therapeutic strategies. Clinical trials exploring the efficacy of various drug combinations and the potential of emerging treatments such as CAR-T cell therapy for lung cancer are gaining momentum. Additionally, collaborations between biotech firms and academic institutions are fostering innovation and accelerating the introduction of breakthrough therapies into the market. Such collaborative efforts are pivotal in addressing unmet medical needs and improving survival rates for lung cancer patients.

Small Cell Lung Cancer Therapeutics have been gaining attention due to the aggressive nature of the disease and the urgent need for effective treatments. Unlike non-small cell lung cancer, small cell lung cancer (SCLC) is known for its rapid growth and tendency to spread quickly, necessitating innovative therapeutic approaches. Recent advancements in the field have focused on developing targeted therapies and immunotherapies that can better manage the disease's progression. Research is ongoing to identify biomarkers that can predict treatment response, which could lead to more personalized and effective therapeutic strategies. The integration of these novel approaches into clinical practice holds promise for improving survival rates and quality of life for patients diagnosed with SCLC.

Regionally, the lung cancer diagnosis and therapeutics market exhibits diverse trends and opportunities. North America and Europe hold significant market shares due to the well-established healthcare infrastructure, high awareness levels, and substantial investment in research and development. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period. This growth is driven by increasing healthcare expenditure, rising incidence of lung cancer, and improving access to healthcare facilities. In contrast, regions like Latin America, the Middle East, and Africa, though currently underpenetrated, present lucrative opportunities for market players due to growing healthcare awareness and the demand for advanced cancer care solutions.

Product Type Analysis

Lung Cancer Therapy Market Outlook

The global lung cancer therapy market size was valued at approximately USD 26.4 billion in 2023 and is anticipated to reach about USD 43.9 billion by 2032, growing at a CAGR of around 6%. This market is expected to witness significant growth due to rising incidences of lung cancer, technological advancements in therapies, and increasing awareness and screening programs worldwide.

One of the primary growth factors driving the lung cancer therapy market is the increasing prevalence of lung cancer globally. Lung cancer remains one of the most common and deadliest cancers, responsible for a considerable number of cancer-related deaths each year. This has led to a substantial demand for effective treatment options. Factors such as smoking, exposure to carcinogens, and genetic predispositions are contributing to the high incidence rates, necessitating advancements and innovations in therapeutic approaches to improve patient outcomes.

Another significant growth driver is the continuous advancement in medical technology and therapies. Innovations in targeted therapy, immunotherapy, and personalized medicine are transforming the treatment landscape for lung cancer. These advancements not only improve survival rates but also enhance the quality of life for patients with fewer side effects compared to traditional treatments like chemotherapy and radiation. The development of novel drugs and the approval of new and effective treatment protocols by regulatory bodies are further contributing to market growth.

Furthermore, increased funding for cancer research and development, along with supportive government initiatives, are propelling the market forward. Governments and private organizations are investing heavily in cancer research to discover and develop more effective therapies. Initiatives such as lung cancer awareness campaigns, early detection programs, and improved healthcare infrastructure in emerging economies are also bolstering the demand for lung cancer therapies, ensuring patients receive timely and effective treatment.

In the realm of oncology, Laryngeal Cancer Therapeutics is gaining attention due to the rising incidence of laryngeal cancer, a type of cancer that affects the voice box. This form of cancer is often linked to smoking and excessive alcohol consumption, similar to lung cancer. The therapeutic landscape for laryngeal cancer is evolving with advancements in targeted therapies and immunotherapies, which are designed to provide more effective and less invasive treatment options. These therapies aim to preserve the larynx and maintain the patient's quality of life, addressing both the physical and emotional aspects of cancer treatment. As research progresses, the integration of innovative treatment modalities in laryngeal cancer therapeutics is expected to improve patient outcomes significantly.

Regionally, North America holds a significant share of the lung cancer therapy market, followed by Europe and the Asia Pacific. The high prevalence of lung cancer, robust healthcare infrastructure, and strong presence of leading pharmaceutical companies are contributing to the market's dominance in these regions. The Asia Pacific region is expected to witness the highest growth rate during the forecast period due to increasing healthcare expenditure, rising awareness, and a growing patient population.

Treatment Type Analysis

The lung cancer therapy market is segmented into various treatment types, including chemotherapy, targeted therapy, immunotherapy, radiation therapy, surgery, and others. Chemotherapy remains a cornerstone in the treatment of lung cancer, despite the advent of newer therapies. It involves the use of potent drugs to kill rapidly dividing cancer cells. While chemotherapy is widely used, it often comes with severe side effects such as nausea, fatigue, and a weakened immune system. However, it is still considered an essential option, particularly in cases where the cancer has spread extensively, and other treatments may not be viable.

Targeted therapy is another significant segment that has gained traction in recent years. It involves the use of drugs designed to specifically target cancer cells while sparing normal, healthy cells. This approach minimizes side effects and improves patient outcomes. Advances in molecular biology and genetics have led to the development of drugs that can block specific pathways involved in cancer growth

Deaths related to cannabis use in England and Wales amounted to 32 in 2023. This was the highest annual amount in the past 30 years. The number of cannabis-related deaths was lowest in 2011,at seven deaths, and since 2014 the annual number of fatalities has remained above twenty. Use of cannabisAccording to a survey, over 30 percent of the English and Welsh public admitted they had consumed cannabis as of 2023. Prevalence of cannabis use in the previous twelve months, however, was at just under eight percent. Generally, cannabis was not regarded to be as dangerous as other illegal or even legal drugs by the public. Over a third of surveyed British individuals considered cannabis to be not harmful, compared to only four percent who thought tobacco is not harmful. Caught green handedIn the period 2022/23, cannabis was by far the most common drug seized by the police and border force in England and Wales. Cannabis was seized over 140 thousand times, with the next highest number of seizures involving cocaine at 19 thousand. Although, the majority of the British public support a policy change regarding the legal status of cannabis. As of 2024, 56 percent of surveyed Brits believed cannabis and other soft drugs should be legalized or decriminalized.

Non-small Cell Lung Cancer Therapeutics Market Outlook

In 2023, the global market size for Non-small Cell Lung Cancer (NSCLC) therapeutics was valued at approximately $12.5 billion, and it is projected to reach around $22.8 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.5%. This impressive growth can be attributed to several factors such as advancements in medical research, increasing prevalence of lung cancer, and the development of new and effective therapeutic options.

One of the significant growth factors driving the NSCLC therapeutics market is the increasing prevalence of lung cancer worldwide. Lung cancer remains one of the most common cancers and a leading cause of cancer-related deaths globally. Factors such as smoking, exposure to hazardous chemicals, and genetic predispositions contribute to the rising incidence of lung cancer. With an aging population and the continued existence of risk factors, the demand for effective NSCLC treatments is anticipated to grow. Additionally, the advent of precision medicine and personalized therapies has ushered in a new era of targeted treatments, significantly improving patient outcomes and fueling market growth.

Another critical factor propelling the market is the innovation and advancement in therapeutic options. Over the years, substantial progress has been made in understanding the molecular and genetic mechanisms underlying NSCLC. This has led to the development of targeted therapies that specifically attack cancer cells with minimal damage to normal cells. Immunotherapy, which leverages the body's immune system to fight cancer, has also shown remarkable success in treating NSCLC. The continuous stream of new drug approvals and the expansion of indications for existing drugs are further expected to drive the market growth.

The growing investments in research and development (R&D) by pharmaceutical companies and research institutions are also pivotal to market expansion. Many leading companies are heavily investing in R&D to discover novel therapeutic targets and develop new drugs. The collaboration between pharmaceutical companies and research organizations is fostering innovation and expediting the development of breakthrough treatments. Additionally, government initiatives and funding to support cancer research are playing a significant role in advancing the NSCLC therapeutics market.

Regionally, North America and Europe have traditionally dominated the NSCLC therapeutics market due to advanced healthcare infrastructure, high healthcare expenditure, and the presence of major pharmaceutical companies. However, the Asia Pacific region is expected to witness significant growth during the forecast period. This can be attributed to the increasing awareness about early cancer diagnosis, improving healthcare facilities, and rising disposable incomes. Government initiatives to enhance cancer care and treatment facilities in countries like China and India are also expected to drive market growth in this region.

Pemetrexed Drug, a well-established chemotherapy agent, plays a crucial role in the treatment of non-small cell lung cancer (NSCLC). It is often used in combination with other chemotherapy drugs and has been shown to improve survival rates in patients with advanced stages of the disease. Pemetrexed works by disrupting the replication of cancer cells, thereby slowing down or stopping their growth. Its efficacy and manageable side effect profile make it a preferred option for many oncologists. Ongoing research is exploring its potential in combination with newer targeted therapies and immunotherapies, aiming to enhance its effectiveness and broaden its application in NSCLC treatment regimens.

By Treatment Type Analysis

The NSCLC therapeutics market can be segmented by treatment type, encompassing chemotherapy, targeted therapy, immunotherapy, radiation therapy, and others. Each of these treatments has unique mechanisms, advantages, and drawbacks, which collectively contribute to the comprehensive management of NSCLC.

Chemotherapy has been a cornerstone in the treatment of NSCLC for many years. It involves the use of cytotoxic drugs to kill rapidly dividing cancer cells. Despite its effectiveness, chemotherapy often comes with significant side effects due to its non-selective nature, affecting both cancerous and healthy cells. However, advancements in chemotherapy protocols and the development of novel agents have impro

In 2022, an estimated ** million cases of acute respiratory infections were reported in Mexico, making them the most common category of illnesses in the country. Urinary tract infections were the second most frequent ailments that year, with *** million cases. Risk factorsSeveral factors can cause respiratory infections; however, they can be exacerbated by activities such as smoking in patients with pre-existing health conditions. Though the smoker population in Mexico has generally declined in the last decade, figures still stand as high as **** million in 2020, and were projected to reach nearly **** million by 2025.Also a heart problemSmoking can also have detrimental effects on heart health. The second leading cause of death in Mexico in 2021 was heart conditions, with *** thousand deaths recorded. Demand for lifesaving transplants has also risen as a result. In 2021, ** patients were placed on the heart transplant waiting list in the North American country, and ** transplants were performed.